Compare BSET & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSET | MXCT |
|---|---|---|
| Founded | 1902 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.9M | 136.0M |
| IPO Year | 1995 | 2021 |
| Metric | BSET | MXCT |
|---|---|---|
| Price | $20.86 | $1.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 104.8K | ★ 1.6M |
| Earning Date | 04-01-2026 | 05-12-2026 |
| Dividend Yield | ★ 5.49% | N/A |
| EPS Growth | ★ 163.06 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $456,855,000.00 | $33,026,000.00 |
| Revenue This Year | $1.72 | N/A |
| Revenue Next Year | $3.78 | $18.50 |
| P/E Ratio | $56.76 | ★ N/A |
| Revenue Growth | ★ 0.96 | N/A |
| 52 Week Low | $13.17 | $0.64 |
| 52 Week High | $21.00 | $2.37 |
| Indicator | BSET | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 76.09 | 67.92 |
| Support Level | $14.29 | $1.19 |
| Resistance Level | N/A | $1.81 |
| Average True Range (ATR) | 1.15 | 0.08 |
| MACD | 0.35 | 0.00 |
| Stochastic Oscillator | 93.45 | 85.26 |
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.